854267-90-6

Usage

Uses

Used in Pharmaceutical Industry:
1-(6-Chloro-pyridin-3-yl)-cyclopropanecarboxylic acid serves as a crucial building block for the synthesis of various drugs and biologically active molecules. Its unique structure allows for the creation of new compounds with potential therapeutic effects, contributing to the development of novel treatments for a range of diseases and conditions.
Used in Agricultural Applications:
While not explicitly detailed in the provided materials, the potential applications of 1-(6-Chloro-pyridin-3-yl)-cyclopropanecarboxylic acid in agriculture could include its use in the development of new pesticides, herbicides, or other agrochemicals. Its role as a building block for synthesis may enable the creation of more effective and targeted agricultural chemicals.
Used in Material Science:
Similarly, the application of 1-(6-Chloro-pyridin-3-yl)-cyclopropanecarboxylic acid in material science is not fully described in the materials, but it can be inferred that its unique properties might be harnessed to develop new materials with specific characteristics. This could involve the creation of advanced polymers, composites, or other materials with applications in various industries.
Research and Development:
1-(6-Chloro-pyridin-3-yl)-cyclopropanecarboxylic acid is a subject of interest for ongoing research and development in the fields of medicinal chemistry and chemical biology. Its structure and properties make it a promising target for exploration, potentially leading to new discoveries and innovations in these scientific disciplines.

Upstream product

• 717106-69-9 methyl 2-(6-chloropyridin-3-yl)acetate 
• 1006875-85-9 methyl 1-(6-chloropyridin-3-yl)cyclopropanecarboxylate 
• 39891-09-3 (6-chloro-pyridin-3-yl)-acetonitrile 
• 107-21-1 ethylene glycol 
• 854267-89-3 1-(6-chloropyridin-3-yl)cyclopropanecarbonitrile 
• 107-04-0 1-Bromo-2-chloroethane 

Downstream Products

• 1402465-72-8 1-(6-{3-methoxy-4-[1-methyl-5-(1,2,2,2-tetradeutro-1-phenylethoxycarbonylamino)-1H-pyrazol-4-yl]-phenyl}-pyridin-3-yl)-cyclopropanecarboxylic acid hydrochloride 
• 1402466-28-7 1-(6-{3-methoxy-4-[1-methyl-5-(1,2,2,2-tetradeutro-1-phenylethoxycarbonylamino)-1H-pyrazol-4-yl]-phenyl}-pyridin-3-yl)-cyclopropanecarboxylic acid 
• 1402466-26-5 methyl 1-(6-(4-(5-amino-1-methyl-1H-pyrazol-4-yl)phenyl)pyridin-3-yl)cyclopropanecarboxylate 
• 1402466-25-4 methyl 1-(6-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyridin-3-yl)cyclopropanecarboxylate 
• 1402465-99-9 methyl 1-(6-(3-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyridin-3-yl)cyclopropanecarboxylate 
• 1402465-98-8 methyl 1-(6-(3-methoxy-4-(trifluoromethylsulfonyloxy)phenyl)pyridin-3-yl)cyclopropanecarboxylate 
• 1402465-97-7 methyl 1-(6-(4-hydroxy-3-methoxyphenyl)pyridin-3-yl)cyclopropanecarboxylate 
• 1268444-84-3 (4R)-4-[(2-chlorophenyl)sulfonyl]-1-{[1-(6-chloropyridin-3-yl)cyclopropyl]carbonyl}-N-(1-cyanocyclopropyl)-L-prolinamide 
• 1268445-09-5 (4R)-1-{[1-(6-chloropyridin-3-yl)cyclopropyl]carbonyl}-4-{[2-chloro-4-(2,2,2-trifluoroethoxy)phenyl]sulfonyl}-N-(1-cyanocyclopropyl)-L-prolinamide 

Relevant academic research and scientific papers

General and cost-effective synthesis of 1-heteroaryl/arylcycloalkylamines and their broad applications

A general and cost-effective route has been developed to synthesize 1-heteroarylsubstituted cycloalkylamines from readily available heteroarylacetate in good yields. This synthesis features a LHMDS promoted cyclization and one-pot hydrolysis/Curtius rearr

COMPOSITIONS AND METHODS FOR MODULATING LPA RECEPTORS

The present invention relates to compounds of Formula (1), or pharmaceutically acceptable salts thereof and their pharmaceutical compositions, wherein variables are as defined herein, which are useful as modulators of the activity of lysophosphatidic acid (LPA).

The discovery of MK-0674, an orally bioavailable cathepsin K inhibitor

MK-0674 is a potent and selective cathepsin K inhibitor from the same structural class as odanacatib with a comparable inhibitory potency profile against Cat K. It is orally bioavailable and exhibits long half-life in pre-clinical species. In vivo studies

CATHEPSIN CYSTEINE PROTEASE INHIBITORS

This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.